Axel Nolting

Statistics

Publications

Citations

433

H-Index

Active since

1997

Affiliations

Merck KGaA, Darmstadt (Germany)(Current)

Queen Mary University of London

Inserm

Rutgers, The State University of New Jersey

Ono Pharmaceutical (United States)

Axel Nolting is an author at Merck KGaA, Darmstadt (Germany) specializing in multiple sclerosis therapy, multiple sclerosis pharmacotherapy, and multiple sclerosis.

ORCID

Publications per year

1997–2023

Publications

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

Stuart D. Cook, Gavin Giovannoni, Per Soelberg Sørensen et al. · Multiple Sclerosis and Related Disorders · 2019 · 142 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis

Stuart D. Cook, Thomas Leist, Giancarlo Comi et al. · Multiple Sclerosis and Related Disorders · 2018 · 122 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis

Thomas Leist, S. D. Cook, Xavier Montalbán et al. · Multiple Sclerosis and Related Disorders · 2020 · 69 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update

Dominic Jack, Doris Damian, Axel Nolting et al. · Multiple Sclerosis and Related Disorders · 2021 · 25 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +10

Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study

Bruno Brochet, Alessandra Solari, Jeannette Lechner‐Scott et al. · Multiple Sclerosis Journal · 2023 · 21 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +12

1–5 of 9